JOHNSON & JOHNSON $86.82

down -0.39


24/5/2013 04:24 PM  |  NYSE : JNJ  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Last Trade: 86.82
Trade Time: May 24 4:10 PM Eastern Daylight Time
Change: -0.39 (-0.45 %)
Prev Close: 87.21
Open: 86.80
Bid: 86.75
Ask: 86.93
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN

ETF Alternatives



People viewing JNJ also viewed: , , , ,

Competitors

Ticker Name Volume % Change
NPCUF ALLON THERAPEUTICS INC 10.0K +1.78%
CNSO CNS RESPONSE 34.1K +1.26%
ISLT ISLET SCIENCES 78.6K +0.75%
ADLS ADVANCED LIFE SCIENCES 35.1K +0.67%
SCLR SCOLR PHARMA 427.3K +0.67%

Insider Transactions

Date Name Title Volume Trade Price Holding Change
5/7/2013 CULLEN JAMES Director -4,929 $85.40 -56.15%
2/8/2013 Caruso Dominic J Chief Financial Officer -4,401 $75.17 -7.60%
2/8/2013 Gorsky Alex Chairman, CEO -4,594 $75.17 -6.20%
2/8/2013 Stoffels Paulus Chief Scientific Officer -9,536 $75.17 -51.57%
2/8/2013 Ullmann Michael H VP, General Counsel -3,789 $75.17 -6.93%
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (JNJ), click here.
View All

JNJ Stock Analysis

  1. Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain

    (MDT,BSX,STJ,JNJ )
    Medtronic continues to suffer with weak core markets, but business seems to be getting slowly better and valuation is not demanding
  2.

    Roche, Reloaded

    (RHHBY,BMY,GILD,MRK,JNJ )
    Roche has one of the best long-term growth profiles in the Big Pharma space
  3.

    Little Left To Dendreon But The Hope Trade

    (DNDN,JNJ,MDVN )
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  4.

    Recent Financials May Not Be Entirely Fair To Hologic

    (HOLX,BDX,QGEN,GE,JNJ,PHG )
    Macro pressures are outweighing solid internal progress at Hologic.
  5.

    In A Growth-Starved Sector, Becton Dickinson Rules

    (BDX,JNJ,HSP,FMS,MDT )
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth.

  6. It Gets A Little Harder From Here For Covidien

    (COV,JNJ,SYK,BCR,MDT,CSII,ISRG,CNMD,ABT )
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
Free Reports
  1.

    Free Managed Futures Book

    Get the four benefits of managed futures as outlined in this booklet.
  2.

    Forbes Wolfe Nanotech Report Nanotech 101

    Get this Rare, First-Person Account of the Nanotechnology Industry, Absolutely Free!
  3.

    Free Corn and Ethanol Report!

    Learn how you can take advantage of an ethanol-driven bull market in corn.
Marketplace
Trading Center